Scandinavian ChemoTech's subsidiary Vetiqure participates in ESVONC's congress in Italy
Between May 26–28th 2022, our product specialist Elin Wallin and our CEO Mohan Frick will participate in ESVONC's annual congress in Italy. A poster on treatment with our TSE™ technology has been accepted and will also be presented there.
The poster that has been accepted is written by Majbritt Larsen, Veterinarian with specialist competence in dog and cat diseases, responsible for Oncology Evidensia Specialist Animal Hospital Helsingborg and presents the outcome from the treatment of sarcoids in a horse, which we published on 16 Nov 2021. Majbritt will herself attend and present her poster at the congress.
“We already had high expectations for this congress, which we believe will give many rings on the water for the continued launch of TSEs in veterinary medicine. The fact that we now also have a poster on TSE that will be presented by Majbritt, in front of many other of Europe's leading veterinarians, gives us the attention that definitely strengthens the chances of continued success. " - says Mohan Frick, CEO and co-founder ChemoTech
ESVONC
The European Society of Veterinary Oncology (ESVONC) was established on September 24th in 1992 by a group of scientists, active in the field of veterinary and comparative oncology in Europe.
- A poster is a scientific summary of a project/study carried out with a positive and interesting outcome that is presented to arouse interest.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
